AU2017222700B2 - Multi-specific molecules - Google Patents

Multi-specific molecules Download PDF

Info

Publication number
AU2017222700B2
AU2017222700B2 AU2017222700A AU2017222700A AU2017222700B2 AU 2017222700 B2 AU2017222700 B2 AU 2017222700B2 AU 2017222700 A AU2017222700 A AU 2017222700A AU 2017222700 A AU2017222700 A AU 2017222700A AU 2017222700 B2 AU2017222700 B2 AU 2017222700B2
Authority
AU
Australia
Prior art keywords
ser
gly
val
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017222700A
Other languages
English (en)
Other versions
AU2017222700A1 (en
Inventor
Phil Anthony JENNINGS
George Kopsidas
Michael Ross Luke
Anthony Simon ROBERTS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imunexus Therapeutics Ltd
Original Assignee
Imunexus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900709A external-priority patent/AU2016900709A0/en
Application filed by Imunexus Therapeutics Ltd filed Critical Imunexus Therapeutics Ltd
Publication of AU2017222700A1 publication Critical patent/AU2017222700A1/en
Application granted granted Critical
Publication of AU2017222700B2 publication Critical patent/AU2017222700B2/en
Priority to AU2019200005A priority Critical patent/AU2019200005A1/en
Assigned to Imunexus Therapeutics Limited reassignment Imunexus Therapeutics Limited Request for Assignment Assignors: IMUNEXUS PTY LTD
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017222700A 2016-02-26 2017-02-27 Multi-specific molecules Active AU2017222700B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019200005A AU2019200005A1 (en) 2016-02-26 2019-01-02 Multi-specific molecules

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2016900709A AU2016900709A0 (en) 2016-02-26 Multi-specific molecules 2
AU2016900708A AU2016900708A0 (en) 2016-02-26 Multi-specific molecules 1
AU2016900709 2016-02-26
AU2016900708 2016-02-26
PCT/AU2017/050168 WO2017143406A1 (en) 2016-02-26 2017-02-27 Multi-specific molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019200005A Division AU2019200005A1 (en) 2016-02-26 2019-01-02 Multi-specific molecules

Publications (2)

Publication Number Publication Date
AU2017222700A1 AU2017222700A1 (en) 2018-03-22
AU2017222700B2 true AU2017222700B2 (en) 2018-09-27

Family

ID=59685848

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017222700A Active AU2017222700B2 (en) 2016-02-26 2017-02-27 Multi-specific molecules
AU2019200005A Abandoned AU2019200005A1 (en) 2016-02-26 2019-01-02 Multi-specific molecules

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019200005A Abandoned AU2019200005A1 (en) 2016-02-26 2019-01-02 Multi-specific molecules

Country Status (7)

Country Link
US (4) US20190338013A1 (https=)
EP (1) EP3419667A4 (https=)
JP (3) JP7536424B2 (https=)
CN (1) CN109310766A (https=)
AU (2) AU2017222700B2 (https=)
TW (1) TW201734037A (https=)
WO (1) WO2017143406A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310766A (zh) * 2016-02-26 2019-02-05 伊蒙纽斯私人有限公司 多特异性分子
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, LLC Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CN110944661A (zh) 2017-02-20 2020-03-31 蜻蜓疗法股份有限公司 结合her2、nkg2d和cd16的蛋白质
JP7173993B2 (ja) 2017-05-19 2022-11-17 ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体
EP3668893A4 (en) * 2017-08-16 2021-08-04 Dragonfly Therapeutics, Inc. PROTEINS BINDING TO NKG2D, CD16 AND EGFR, HLA-E, CCR4, OR PD-L1
CN117050184A (zh) 2017-12-28 2023-11-14 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
KR20200118423A (ko) * 2018-01-08 2020-10-15 난징 레전드 바이오테크 씨오., 엘티디. 다중특이성 항원 결합 단백질 및 이의 사용 방법
CN111699200B (zh) 2018-01-15 2023-05-26 南京传奇生物科技有限公司 针对pd-1的单域抗体和其变体
CA3237846A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
BR112020015994A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
KR102835308B1 (ko) 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
CA3122773A1 (en) 2018-12-26 2020-07-02 Xilio Development, Inc. Anti-ctla4 antibodies and methods of use thereof
EP3927722A4 (en) * 2019-02-18 2022-11-23 Courier Therapeutics, Inc. BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS L-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER
EP3947460A4 (en) * 2019-03-26 2023-05-10 Forty Seven, Inc. MULTISPECIFIC AGENTS FOR TREATMENT OF CANCER
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
EP4093745A4 (en) * 2020-01-20 2024-03-06 Wuxi Biologics Ireland Limited NEW WASH BUFFER SOLUTION FOR AFFINITY CHROMATOGRAPHY
EP3904378A1 (en) * 2020-04-29 2021-11-03 Hober Biotech AB Bispecific protein
JP7512394B2 (ja) 2020-05-06 2024-07-08 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
JP2023545135A (ja) * 2020-10-12 2023-10-26 グレフェックス， インコーポレイテッド ＳＡＲＳ－ＣｏＶタンパク質発現細胞に対するＴ細胞応答を標的にする抗体コンストラクト、それらの設計および使用
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
EP4308608A4 (en) * 2021-03-16 2025-05-07 JN Biosciences LLC BIFUNCTIONAL MOLECULES FOR THE TREATMENT OF IMMUNE DISEASES
JP2024543164A (ja) * 2021-11-26 2024-11-19 イミュネクサス・セラピューティクス・リミテッド 細胞表面上の結合ドメイン分子
CN115078718B (zh) * 2022-07-22 2024-11-12 福建师范大学 一种基于表面增强拉曼技术检测透明质酸酶的方法
KR20250087648A (ko) * 2022-11-09 2025-06-16 리플리겐 코포레이션 친화도 제제

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008096158A2 (en) * 2007-02-08 2008-08-14 Domantis Limited Antibody single variable domains against serum albumin
WO2010136492A2 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP221098A0 (en) * 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
WO2000060070A1 (en) * 1999-04-01 2000-10-12 Innogenetics N.V. A polypeptide structure for use as a scaffold
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US20090148905A1 (en) * 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
NO2344540T3 (https=) * 2008-10-02 2018-04-28
WO2010136485A1 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins
CN109310766A (zh) * 2016-02-26 2019-02-05 伊蒙纽斯私人有限公司 多特异性分子
JP2024543164A (ja) * 2021-11-26 2024-11-19 イミュネクサス・セラピューティクス・リミテッド 細胞表面上の結合ドメイン分子

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008096158A2 (en) * 2007-02-08 2008-08-14 Domantis Limited Antibody single variable domains against serum albumin
WO2010136492A2 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins

Also Published As

Publication number Publication date
US20240182542A1 (en) 2024-06-06
EP3419667A1 (en) 2019-01-02
JP2022105574A (ja) 2022-07-14
EP3419667A4 (en) 2019-10-23
US20190338013A1 (en) 2019-11-07
WO2017143406A1 (en) 2017-08-31
AU2019200005A1 (en) 2019-01-24
TW201734037A (zh) 2017-10-01
AU2017222700A1 (en) 2018-03-22
JP2019510812A (ja) 2019-04-18
JP7536424B2 (ja) 2024-08-20
US20210040177A1 (en) 2021-02-11
US11345736B2 (en) 2022-05-31
US20210230249A1 (en) 2021-07-29
CN109310766A (zh) 2019-02-05
JP2024026531A (ja) 2024-02-28

Similar Documents

Publication Publication Date Title
AU2017222700B2 (en) Multi-specific molecules
JP7076152B2 (ja) ＩｇＧ結合ペプチドによる抗体の特異的修飾
US12324837B2 (en) ROR1-specific antigen binding molecules
KR102845959B1 (ko) Psma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
US11845793B2 (en) Anti-ROR1 antibodies
JP7482488B2 (ja) Ｃｄ１３７とｐｄ－ｌ１に特異的な新規融合タンパク質
RS61586B1 (sr) Anti-tfr antitela i njihova upotreba u lečenju proliferativnih i zapaljenjskih poremećaja
KR20260028110A (ko) 이중특이성 t 세포 맞물림 항체 작제물
CN116761815A (zh) T细胞和嵌合刺激受体及其应用
JP2012511032A (ja) ＳＰＡＲＣ結合ＳｃＦｖ
KR20170110601A (ko) 시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물
JP7295098B2 (ja) 新規抗ｃｄ１９抗体
JP2023540526A (ja) ネクチン－４抗体およびそれの使用
WO2012071649A1 (en) Covalently dimerized bivalent binding agents
KR20220161362A (ko) 다중특이적 항체를 작제하기 위한 플랫폼
CN119137147A (zh) 具有增加的选择性的多链多靶向性双特异性抗原结合分子
CN113461820B (zh) 抗cd3人源化抗体
CN113461821B (zh) 抗cd3人源化抗体
Marshall et al. Engineering and characterization of a novel fusion protein incorporating B7. 2 and an anti–ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells
KR20230098335A (ko) 클리핑 비율이 감소된 항원 결합 도메인
WO2023029089A1 (zh) 抗cd3人源化抗体
CN112543772A (zh) 双特异性抗体
JP7854204B2 (ja) 新規ｉｉ型コラーゲン結合タンパク質
CN121358496A (zh) T细胞接合器掩蔽分子

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: IMUNEXUS THERAPEUTICS LIMITED

Free format text: FORMER OWNER(S): IMUNEXUS PTY LTD